Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

MTTI Receives Chinese Patent for EVATHERA Technology


Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of Chinese Patent CN109153641B covering MTTI's lead radiotherapeutic product, EBTATEtm and others in its EvaTheratm platform. Approval of "Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents" follows issued patents in the US, Europe, Singapore, and Japan this past year.

EBTATE is a new generation of peptide receptor radiotherapeutic drug that has demonstrated potential clinical superiority over standard of care. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine and other tumors, which are then killed by the radionuclide. EvaThera platform products were designed to bind to serum albumin, due to the Evans blue moiety, extending in vivo residence time, enabling lower, less frequent dosing of the radiopharmaceutical and reducing risk of renal injury vs. the current standard of care.

Our recent 3-year follow-up report on a 30-patient, ex-US, EBTATE study showed stable disease with progression-free survival of 43 months after three cycles of EBTATE. EBTATE treatment is effective and less toxic for neuroendocrine tumor patients. *

Chris Pak, MTTI's President & CEO, commented, "This complements our IP portfolio, further protecting our EvaThera platform." He added, "We're continuing to bolster our position in radiotheranostics with planned clinical trials of our two platform products in multiple indications."

About Molecular Targeting Technologies, Inc. (MTTI)

Molecular Targeting Technologies, Inc., is a privately held, rapidly growing, well financed, clinical-stage biotech company developing next-generation targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostics assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2023. For more information: www.evathera.com

See* below:

https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=36701


These press releases may also interest you

at 08:16
The TeamConnor Childhood Cancer Foundation is proud to continue its work towards eradicating pediatric cancer by awarding $500,000 to multiple research grantees at five national institutions to fund their childhood cancer research work in 2023. As...

at 08:10
Agilent Technologies Inc. today announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems. The compliance-enabling features enable users to meet regulatory requirements defined...

at 08:10
Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive...

at 08:05
Reshape Biotech, an integrated hardware and software platform digitizing microbiology experiments, today announced an $8.1 million investment, Denmark's largest-ever seed round. The oversubscribed investment was led by ACME Capital, with...

at 08:05
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , has reached agreement with the Attorney General of Florida to settle the state's price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the...

at 08:05
Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") , a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of...



News published on 6 december 2022 at 06:05 and distributed by: